Engflag

Cebutol

Quick links to important sections

Cebutol

Cebutol_EN

Method of action: Antianginal, Antiarrhythmic, Antihypertensive, Beta Blocking Agents, Hypotensive

Treatment option: Arrhythmia, Hypertension, Angina Pectoris, Tachycardia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cebutol

Quick Facts

Property Description
Active Ingredient Acebutolol hydrochloride
Form Oral tablet or capsule
Pharmacological Class Selective Beta-blocker (beta1 blocker)
General Purpose To reduce heart workload and stabilize rhythm
Origin Synthetic (chemically produced)

What Type of Medicine is Cebutol?

Cebutol is a brand name for the active ingredient acebutolol, which belongs to a major class of heart and blood pressure medications known as selective beta-blockers. It is a prescription-only medicine (Rx) that works by affecting specific chemical receptors primarily located in the heart. This action helps to regulate heart activity and the pressure within the blood vessels.

Unlike non-selective beta-blockers, Cebutol is considered selective because it mainly targets the beta1 receptors concentrated in the heart muscle. The medicine is classified as a synthetic compound, meaning it is chemically manufactured rather than derived directly from natural sources. Cebutol is typically taken by mouth, most often in the form of an oral tablet or capsule.

Composition and Form: What's in a Cebutol Tablet?

The entire therapeutic action of Cebutol comes from a single active substance: acebutolol hydrochloride. This makes Cebutol a single-entity medicine, meaning it is not combined with other active ingredients in the same pill. Pharmacological studies have noted that acebutolol has a unique property known as Intrinsic Sympathomimetic Activity (ISA). This property means the drug not only blocks but also partially stimulates the heart receptors, which may offer a more balanced effect on the heart rate compared to some other beta-blockers, a point that is clinically recognized.

In addition to the active drug, Cebutol tablets or capsules contain standard pharmaceutical excipients—non-active components like binders, fillers, and coatings—that help hold the medicine together and ensure it dissolves correctly in the body.

What is the General Purpose of Taking Cebutol?

The general purpose of Cebutol is to reduce the workload and stress on the heart muscle, leading to a more regulated and efficient cardiovascular system. By blocking the effects of natural stress hormones, like adrenaline, on the heart, it causes the heart to beat more slowly and less forcefully. This fundamental action is recognized in pharmacological research.

This calming effect helps stabilize an overactive or irregular heartbeat and reduces the physical force the blood exerts on the walls of the arteries. The ultimate goal is to promote long-term heart health by fostering a more stable and less strained heart rhythm.

Regulatory References

  1. Public Assessment Report (Acebutolol)

What side effects are possible with Cebutol?

Possible Side Effects and Safety Information

The safety profile of Cebutol (acebutolol) is established through government regulatory documents and is classified by frequency and the body system affected. The list below reflects officially documented adverse reactions and key safety constraints.

Adverse Reaction Classifications

Adverse effects are categorized based on their documented frequency in clinical use:

  • Common Reactions (occurring in up to 1 in 10 patients) often involve the Nervous System and Gastrointestinal System. These include fatigue, headache, dizziness, and GI disturbances such as diarrhea or nausea. Many common effects may be observed more frequently during the initiation of treatment.
  • Uncommon and Rare Reactions cover effects such as insomnia, depression, visual disturbances, and sexual dysfunction. Rare effects include bronchospasm and certain skin reactions.

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions primarily involve the Cardiovascular System. The official label identifies the potential for severe bradycardia (excessively slow heart rate), pronounced hypotension, and the worsening of existing heart failure.

Cebutol is contraindicated and should not be used in individuals with pre-existing severe cardiac conditions, including cardiogenic shock, overt cardiac failure, and advanced atrioventricular (AV) block. Additionally, specific safety consideration and monitoring are noted for patients with renal impairment, as acebutolol is primarily eliminated through the kidneys.

Overdose and Emergency Response

The official regulatory profile for Cebutol (Acebutolol) overdose focuses strictly on the profound effects resulting from excessive pharmacological action. Documented overdose presentations primarily involve severe cardiovascular depression, which includes extreme slowing of the heart rate (bradycardia), critically low blood pressure (hypotension), fainting (syncope), and severe congestive heart failure.

Beyond cardiac signs, official labeling notes systemic neurological and respiratory manifestations, such as seizures (convulsions), confusion, and troubled breathing or wheezing. The risk of life-threatening escalation is explicitly addressed, with coma and death listed as potential severe outcomes of unmanaged toxicity.

Immediate medical attention is required for any suspected overdose. Official guidance mandates calling emergency services (e.g., 911) if the affected person has collapsed, is seizing, or cannot be awakened. Management is symptomatic and supportive, utilizing specific interventions like beta-receptor agonists and atropine to counteract severe cardiac effects. Furthermore, continuous monitoring of vital signs and an electrocardiogram (ECG) is required, often necessitating an overnight hospital stay. A specific consideration notes that low blood sugar (hypoglycemia) is a documented risk in children following beta-blocker overdose.

Therapeutic Uses of Cebutol

Quick Facts

Condition
Management of elevated blood pressure (hypertension)
Management of certain types of irregular heart rhythms (ventricular arrhythmias)
Management of stable angina pectoris

Cebutol (acebutolol) is a prescription medication utilized in therapeutic regimens for various heart- and circulation-related conditions. This treatment option is approved for the management of hypertension in adults and may be used as a standalone approach or in conjunction with other agents, such as thiazide-type diuretics.

It is also indicated in the management of ventricular premature beats. In this setting, the medication may help to reduce the total number of premature beats, as well as the frequency of certain other ectopic heart rhythms. Furthermore, Cebutol can be utilized to address the symptoms of chronic, stable angina pectoris.

Patients should always discuss their condition and appropriate treatment plan with a healthcare professional to determine if Cebutol is a suitable component of their care.

Regulatory References

  1. FDA drug label guidance

Eligibility and Restrictions for Use

Cebutol (acebutolol hydrochloride) is restricted to use only in adults and is contraindicated in patients with specific, serious cardiac conditions.

Populations Strictly Prohibited (Contraindicated)

  • Persistently severe bradycardia (abnormally slow heart rate).
  • Second- and third-degree heart block (a type of electrical conduction delay in the heart).
  • Overt cardiac failure (symptomatic or decompensated heart failure).
  • Cardiogenic shock (a life-threatening condition where the heart cannot pump enough blood).

Populations Requiring Caution/Restriction

Population/Condition Eligibility Status/Constraint
**Pediatric Patients** Safety and effectiveness **have not been established**.
**Bronchospastic Disease** Use is **not recommended** in general; if necessary, it must be used with **caution** at low doses for those who cannot tolerate or do not respond to alternative treatments.
**History of Heart Failure** May be used with **caution** only in patients whose heart failure is currently controlled (e.g., with digitalis and/or diuretics).
**Renal Impairment** Administer with **caution** due to decreased elimination of the active metabolite, requiring dosage adjustment (e.g., dose reduction by 50% for CrCl 25-49 mL/min).
**Pregnancy** Use only if clearly needed (**Pregnancy Category B**).
**Lactation (Breastfeeding)** Acebutolol passes into breast milk. A decision must be made to **discontinue nursing or discontinue the drug**.
**Peripheral Vascular Disease** Use with **caution**, as treatment can precipitate or aggravate symptoms of arterial insufficiency.

The regulatory profile outlines rigid constraints against using the medicine in severe cardiovascular failure states. While use is permitted in adults for listed indications, the label strictly enforces caution and potential dose adjustments for individuals with certain organ impairments or other pre-existing heart or lung conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cebutol (acebutolol) interactions are primarily defined by pharmacodynamic effects and the clearance pathway of its active metabolite, diacetolol, as detailed in regulatory documents.

Formally Contraindicated Combinations

Co-administration with certain agents is formally prohibited by regulatory authorities due to the risk of severe cardiac depression or excessive bradycardia. These include non-dihydropyridine calcium channel blockers (such as verapamil and diltiazem) and some other agents like the antipsychotic Sultopride and the analgesic Floctafenine.

Documented Pharmacodynamic and Exposure Interactions

Interacting Agent Category Officially Documented Interaction Outcome
Other Beta-Blockers / Antiarrhythmics Additive effects may increase the risk of bradycardia and heart block.
Antidiabetic Agents May mask certain symptoms of hypoglycemia (e.g., tachycardia), requiring intensified glucose monitoring.
NSAIDs (long-term use) May decrease Cebutol's antihypertensive activities due to pharmacodynamic antagonism.
Sympathomimetic Agents Risk of increased blood pressure due to unopposed alpha-adrenergic stimulation.

Timing and Population-Specific Restrictions

Administration of Cebutol and multivitamin with minerals must be separated by at least 2 hours to prevent a reduction in Cebutol's intended effect. The active metabolite, diacetolol, is primarily eliminated by the kidney; therefore, the official label requires a reduction in the daily dose for patients with impaired renal function due to decreased clearance and increased exposure.

Mechanism of Action

VDR Agonism and Nuclear Signaling

Cebutol is a synthetic analogue that selectively agonizes the Vitamin D Receptor (VDR), a nuclear receptor found in target cells, including those in the kidney and bone. This binding event initiates a conformational change in the VDR, facilitating its heterodimerization with the Retinoid X Receptor (RXR). This VDR-RXR complex then translocates to the nucleus where it interacts with specific DNA sequences, known as Vitamin D Responsive Elements (VDREs), located in the promoter regions of target genes. The resulting genomic signaling cascade modulates the expression of genes involved in systemic mineral homeostasis.

Mineral Homeostasis and Bone Cell Modulation

Cebutol influences the activity of parathyroid hormone and calcitonin receptors, influencing calcium and phosphate ion flux. This modulation of renal reabsorption affects ion transport, leading to an alteration in the concentration of circulating active Vitamin D metabolites. Furthermore, it decreases the synthesis of osteoclast-activating factors and upregulates osteoblast differentiation markers. The drug also affects the kinetics of hydroxyapatite dissociation in bone matrix.

Dosage and Administration Information

How to Use Cebutol: Official Administration Guidelines

Cebutol, the brand name for acebutolol hydrochloride, is a prescription medicine whose usage is defined by established prescribing information. This section outlines the standardized administration protocol concerning dose, frequency, and specific intake conditions as stated in pharmaceutical documentation.

Administration Scope

Category Administration Instruction
Route of Administration Cebutol is administered solely via the oral route as a capsule or tablet.
Intake Condition The dose should be taken with food or after a meal and must be swallowed whole with water; the tablet should not be crushed or chewed.
Dose Titration Initial dose adjustment is typically performed at weekly intervals to find the optimal regimen.

Official Dosing and Frequency Patterns

The established dosage patterns detail starting, maintenance, and maximum daily amounts. For the management of elevated blood pressure (hypertension) or angina pectoris, the usual starting dose is 400 mg daily, which may be taken as a single dose or divided into two doses. The standard maintenance range is 400 mg to 800 mg per day, with the maximum recommended dose set at 1200 mg daily. Treatment for ventricular arrhythmias often begins with a divided 400 mg daily dose, often as 200 mg twice daily.

Special Procedural Requirements

Usage protocols require dose modification in certain patient populations. For individuals with renal impairment, established protocols specify a dose reduction of 50% or 75% based on the severity of kidney function. Furthermore, treatment is intended for long-term chronic use. When discontinuing the medication, the dosage must be reduced gradually over a period of about two weeks; abrupt cessation is not part of the labeled protocol.

Recent Clinical Evidence

Cebutol: Recent Clinical Evidence

The clinical research for Cebutol (acebutolol) is primarily structured around its use in managing high blood pressure, certain heart rhythm problems, and chronic stable chest pain. This overview describes the types of studies conducted for these uses, what the research monitored, and where limitations or knowledge gaps exist according to scientific documentation. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Evidence for Use in Managing Elevated Blood Pressure (Hypertension)

Research exploring Cebutol for hypertension was evaluated in various controlled settings, including short-term Randomized Controlled Trials (RCTs). Studies monitored outcomes related to blood pressure level measurements and heart rate. Certain comparative studies documented that researchers measured a difference in the change of resting heart rate for Cebutol compared to some other medicines in the same class. Reported measurements often focused on the acute effects on BP over short treatment periods. Long-term data focusing on Cebutol's direct link to major long-term cardiovascular events is still emerging and is often extrapolated from larger drug class reviews.

Evidence for Use in Managing Irregular Heart Rhythms (Ventricular Arrhythmias)

Research on the antiarrhythmic properties of Cebutol was studied for conditions characterized by episodic manifestations through small-scale, double-blind, randomized, placebo-controlled crossover studies. These studies primarily examined outcomes related to the frequency and complexity of abnormal heartbeats. The studies report how symptoms evolved in the observed populations, describing patterns related to the measured count of abnormal heartbeats during the short intervention phases. A key limitation is that trials generally focused on surrogate endpoints (like the count of extra heartbeats) rather than definitive long-term outcomes like survival or hospitalization rates.

Evidence Gaps and Areas of Uncertainty

Comparative evidence is lacking for Cebutol against many of the newer, more common classes of anti-hypertensive drugs. Furthermore, the evidence base is limited by modest sample sizes in certain older studies, and data for specific groups, like pediatric populations, remains insufficient. Regulatory documents describe patterns related to drug exposure in older patients, suggesting that drug metabolism was different in this group.

Key Studies & References

  1. Acebutolol Hydrochloride Capsules FDA Label (DailyMed)
  2. Acebutolol for lowering blood pressure in adults: a systematic review and meta-analysis of randomized controlled trials

How should Cebutol be stored and disposed of?

How to Store and Dispose of Cebutol (Acebutolol)

Official regulatory guidelines mandate specific conditions for storing and disposing of Cebutol (acebutolol hydrochloride) to ensure product stability and public safety.

Storage Conditions

Requirement Details
Temperature Must be stored at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), with permitted excursions up to 30 C.
Protection Store in the original container, kept tightly closed, and protected from excess heat and moisture.
Child Safety The medication must be kept out of the sight and reach of children.

Disposal Instructions

Regulatory instructions require that expired or unused Cebutol not be disposed of in household trash or poured down a sink or toilet. Disposal must comply with local requirements. Patients are directed to consult a pharmacist for guidance on proper pharmaceutical waste disposal or to utilize a medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTunisia

Equivalent of Cebutol found in:

A-Z Index: